GSK is focused on maximizing patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody-drug conjugates and cell therapy, either alone or in combination.
Brands: https://cloud.bgbdigital.com/gsk-oncology/GSKOFR_ASCO-Booth-Banner.jpg
Show Specials
Press Releases